Deals channel feed – Endpoints News

Deals channel feed

Merck KGaA closes in on SpringWorks deal at $3.5B price point

5 weeks ago

Bristol Myers CEO signals dealmaking will be a top priority in 2025

Last month

Roche CEO warns that tariffs could impact dealmaking

Last month

China’s biotech market is staging a comeback that US biotech can only wish for

Last month

Repertoire inks autoimmune deal with Genentech as it eyes a return to the clinic

Last month

Boehringer taps Dutch biotech for ALT positive cancer pact exceeding $573M in biobucks

Last month

Exclusive: VelaVigo inks another US biotech deal as China drug development scene booms

Last month

Sanofi to pay $125M upfront for two immunology drugs from little-known biotech

Last month

Ayrmid misses deadline for detailed offer to top private equity bid for bluebird

Last month

GeneDx to buy Fabric Genomics for up to $51M

Last month

Exclusive: A small biotech will bring Roche's Angelman drug back to life

Last month

Merck explores potential of oral peptides in deal with Austrian biotech

Last month

What's Pfizer's next move after shelving its oral obesity drug danuglipron?

Last month

Tempest seeks strategic alternatives to fund Phase 3 liver cancer trial

Last month

Market turmoil is tanking biotech M&A and IPOs. Here's the playbook startups will use to survive

Last month

PureTech rejects cash exit proposal from Nordic Capital, investment firm says it won't make an offer

Last month

GSK’s newest neuro pact is with ABL Bio, a Sanofi-partnered South Korean biotech

Last month

Eli Lilly pays struggling Sangamo $18M upfront to tap gene therapy capsid

Last month

F-star management takes company private, two years after $161M cash exit to Sino's invoX

Last month

Tang Capital's Concentra nabs a win, making a deal to buy Allakos

Last month

New CDMO emerges, acquires cell and gene manufacturer Landmark Bio

Last month

Bluebird gets new M&A bid, seeking to top private equity offer

Last month

Novo inks second obesity deal of the week, with Lexicon oral drug partnership worth up to $1B

Last month

Before Alumis went public via IPO, it tried doing a reverse merger with Acelyrin

Last month

First page Previous page 123 4 5 Next page Last page